Purchase Option

$ 4400
$ 4000
$ 6000

Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018  

Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment

  Overview: Juvenile Idiopathic Arthritis is a most common arthritis in children. It is the inflammation of one or more joints. JIA is more common in girls. There are six different types of JIA, the symptoms may vary from type to type. Most common symptoms and signs include painful and swollen joints, stiffness in joints, joints becomes warm to touch, tiredness, relapsing fever, appearance of limp. JIA may occur because of immune system attacks or certain gene mutations. JIA is diagnosed by blood tests for Cycliccitrullinated peptide (CCP), Anti-nuclear antibody, C-reactive protein, Rheumatoid factoretc and also by CT-Scan and MRI scan. Treatment for JIA includes NSAID’S, DMARD’s (Disease-modifying antirheumatic drugs), Biologics and corticosteroids, if the condition get worsen then surgery is recommended.   Segmentation: By Trial Phase, Juvenile Idiopathic Arthritis pipeline drugs are segmented as:
  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
By Company, Juvenile Idiopathic Arthritis pipeline drugs are segmented as:
  • Novartis
  • Sanofi
  • RegeneronPharmaceuticals
  • medac GmbH
  • UCB BIOSCIENCES GmbH
  • F Hoffmann-La Roche
  • Pfizer
  • Bristol-Myers Squibb
  • Eisai Co., Ltd.
  • Abbott Laboratories
  • Others
By Drugs, Juvenile Idiopathic Arthritis pipeline drugs are segmented as:
  • Sarlumab
  • Abatacept
  • CertolizumabPegol
  • Adalimumab
  • Tocilizumab
  • Canakinumab
  • Tofacitinib
  • Others
By Type of Condition Juvenile Idiopathic Arthritis pipeline drugs are segmented as:
  • Systemic JIA
  • Oligoarthritis
  • Polyarticular arthritis,rheumatoid factor negative/ rheumatoid factor positive
  • Psoriatic arthritis
  • Enthesitis-related arthritis
  • Undifferentiated arthritis
By Route of Administration, Juvenile Idiopathic Arthritis pipeline drugs are segmented as:
  • Oral
  • Parenteral
  Space Analysis:
  • InNovember 2014, Novartis Pharmaceuticals commenced Phase III an open-label canakinumab (acz885) dose reduction or dose interval prolongation efficacy and safety study in patients with systemic juvenile idiopathic arthritis
  • In 22013, Pfizer commenced a long-term, phase 2/3 open-label follow-up study of tofacitinib for treatment of juvenile idiopathic arthritis
  Report Description: Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Juvenile Idiopathic Arthritis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Juvenile Idiopathic Arthritis disease pipeline drugs development. This report studies the dynamics of the Juvenile Idiopathic Arthritis Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Juvenile Idiopathic Arthritis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.   Key Features of the Report:
  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases
 

Location

GEOGRAPHY

PBI Location Map

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

[urltag url='request-table-of-content']

 

  • Novartis
  • Sanofi
  • RegeneronPharmaceuticals
  • medac GmbH
  • UCB BIOSCIENCES GmbH
  • F Hoffmann-La Roche
  • Pfizer
  • Bristol-Myers Squibb
  • Eisai Co., Ltd.
  • Abbott Laboratories

Adjacent Markets